^
Association details:
| Biomarker: | KIT exon 11 mutation + KIT exon 17 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) + IPI 493 (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations
Excerpt:
The combination of IPI-493 with SUN remarkably enhances antitumor effects in GIST, especially in tumors carrying double KIT mutations.
DOI:
10.1158/1078-0432.CCR-11-0562
